Effects of rocuronium-induced neuromuscular blockade with sugammadex on diaphragm in rats

Aim: Sugammadex is a recently developed γ-cyclodextrin agent that can reverse the effects of blockers such as rocuronium used to maintain non-depolarizing neuromuscular blockade. In this study, it was aimed to determine the effects of rocuronium and sugammadex applied to rats on the diaphragm. Materials and Methods: A total of 32, 8-10 week old Sprague-Dawley male rats were used in the study. Experimental animals were divided into 4 groups with 8 animals in each group. The control group did not receive any application with an experimental period. The sham group was given a volume of physiological saline equivalent to 16 mg/kg Sugammadex. Sugammadex group received 16 mg/kg sugammadex and sugammadex+rocuronium group received 16 mg/kg sugammadex followed by 1 mg/kg rocuronium. At the end of the experiment, diaphragms of all rats were removed. Tissues were evaluated histopathologically for the location of nuclei in the fibers, their serosal structures, cell infiltrations, fiber diameter and changes in morphology. Results: The cores of the fibers were located in the peripheral areas in sugammedex examinations. In this group, interstitial edema and an increased number of fibers were detected with some morphological changes compared to the Sham and Control Group. The diameters of the fibers were decreased compared to the Sham and Control Group. In the cross-sectional images of the rocuronium-sugammadex Group, it was found that the fiber diameter decreased compared to other groups, and edema increased in the interstitial area. This difference was found to be significant according to the statistical analysis using histopathological scoring (p < 0.05).The increase in the fibers undergoing morphological changes was at a significant level. Conclusion: Sugammadex and Rocuronium-Sugammadex Complexes cause histopathological changes in diaphragmatic cells.

PDF

___

1. Brett K, Farrah K. Sugammadex for the Reversal of Rocuronium-Induced Neuromuscular Blockade in Surgical Patients: A Review of Clinical Effectiveness [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. 2019.
2. Kawano T, Yokoyama M. Can sugammadex encapsulation eliminate the antigenic activity of aminosteroidal neuromuscular blocking agent? J Anesth [Internet]. 2011;25(6):953–4.
3. Uludağ O. Effect of Sugammadex and Rocuronium Combination on Cranial Neurotoxicity in Rats: Experimental Study. Kafkas Üniversitesi Veteriner Fakültesi Dergisi [Internet]. 2019;25.
4. Grosse-Sundrup M, Henneman JP, Sandberg WS, et al. Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study. BMJ [Internet]. 2012;345(oct15 5):e6329.
5. Arnardottir S, Alexanderson H, Lundberg IE, Borg K. Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction. J Rehabil Med [Internet]. 2003;35(1):31–5.
6. Karayiannakis AJ, Makri GG, Mantzioka A, et al. Postoperative pulmonary function after laparoscopic and open cholecystectomy. Br J Anaesth [Internet]. 1996;77(4):448–52.
7. Yuzkat N, Kati I, Isik Y, et al. Effects of theophylline with methylprednisolone combination therapy on biomechanics and histopathology in diaphragm muscles of rats. Inflammation [Internet]. 2016;39(5):1635–41.
8. Jaber S, Jung B, Matecki S, Petrof BJ. Clinical review: Ventilator-induced diaphragmatic dysfunction - human studies confirm animal model findings! Crit Care [Internet]. 2011;15(2):206.
9. Maes K, Testelmans D, Thomas D, et al. High dose methylprednisolone counteracts the negative effects of rocuronium on diaphragm function. Intensive Care Med [Internet]. 2011;37(11):1865–72.
10. Uludag O. History and importance of ethical rules in animal experiment studies. Adıyaman Üni Sağlık Bilimleri Derg [Internet]. 2019;5(1):1401–13.
11. Cammu G, De Kam PJ, Demeyer I, et al. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. Br J Anaesth [Internet]. 2008;100(3):373–9.
12. Inder WJ, Jang C, Obeyesekere VR, Alford FP. Dexamethasone administration inhibits skeletal muscle expression of the androgen receptor and IGF-1-implications for steroid-induced myopathy. Clinical endocrinology. 2010;73(1):126–32.
13. Testelmans D, Maes K, Wouters P, et al. Infusions of rocuronium and cisatracurium exert different effects on rat diaphragm function. Intensive Care Med [Internet]. 2007;33(5):872–9.
14. Yoshioka N, Hanazaki M, Fujita Y, et al. Effect of sugammadex on bronchial smooth muscle function in rats. J Smooth Muscle Res [Internet]. 2012;48(2_3):59–64.
15. Eikermann M, Zaremba S, Malhotra A, et al. Neostigmine but not sugammadex impairs upper airway dilator muscle activity and breathing. Br J Anaesth [Internet]. 2008;101(3):344–9.
16. Ünal N. Suna Danışman Sugammadeks’ in sıçanların iskelet kas yapısına etkisi (Ankara Üniversitesi Fen Bilimleri Enstitüsü Doctoral dissertation). 2018.
17. Kalkan Y, Bostan H, Tumkaya L, et al. The effect of rocuronium, sugammadex, and their combination on cardiac muscle and diaphragmatic skeletal muscle cells. Journal of anesthesia. 2012;26(6):870–7.